Background: Biosimilars provide opportunities for improving healthcare access and outcomes and reducing overall healthcare costs for patients with cancer.
Objectives: The purpose of this article is to explore the history of biosimilars, regulatory pathways, and barriers to biosimilar approval. This article also aims to describe the patient and clinician barriers to biosimilars use and the progress that has been achieved since the first biosimilar approval in Europe in 2006 and in the United States in 2015.
Methods: A literature search was conducted to retrieve articles that are highly relevant to the history of biosimilars development and regulatory pathways in the United States, Europe, Asia, and Canada. Patient and clinician perspectives on safety issues and concerns regarding immunogenicity and bioequivalence that limit use of biosimilars are also included.
Findings: Patient and provider concerns regarding immunologic patient safety issues, such as immunogenicity, lack of comparability, and low biosimilarity, still exist. The clinical safety, efficacy, and tolerability of biosimilars are among the top concerns in patients, prescribers, and clinicians.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1188/18.CJON.S1.5-12 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Opioids and benzodiazepines in oncology: Perspectives on coprescribing and mitigating risks.
J Geriatr Oncol
December 2024
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, United States. Electronic address:
Introduction: Opioids and benzodiazepines are commonly prescribed for cancer symptoms. In combination, they can increase the risk of adverse events, particularly for older adults with multimorbidity, who represent most patients with cancer. We aimed to understand cancer care providers' practices for opioid and benzodiazepine coprescribing and mitigating potential harms.
View Article and Find Full Text PDFComparison of Reference and Biosimilar Medications for Pediatric Noninfectious Uveitis.
Int Ophthalmol Clin
October 2024
Department of Ophthalmology, Duke University, Duke Eye Center, Durham, NC.
Objective/purpose: Compare outcomes and costs of TNF-alpha inhibitor biosimilars to reference medications in the treatment of pediatric NIU.
Methods: Patients 18 years old or below treated with reference or biosimilar TNF-alpha inhibitor for noninfectious uveitis and had a history of active ocular inflammation with at least 1 month of ophthalmology follow-up from January 1, 2013, to June 1, 2023, were included. Retrospective chart review was performed.
History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region.
Front Pharmacol
August 2024
Territorial Pharmaceutical Assistance Unit, Azienda ULSS 9 Scaligera, Verona, Italy.
A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates.
Front Immunol
July 2024
Patronus Biotech Co. Ltd., Guangzhou, China.
Herpes zoster (HZ), also known as shingles, remains a significant global health issue and most commonly seen in elderly individuals with an early exposure history to varicella-zoster virus (VZV). Currently, the licensed vaccine Shingrix, which comprises a recombinant VZV glycoprotein E (gE) formulated with a potent adjuvant AS01B, is the most effective shingles vaccine on the market. However, undesired reactogenicity and increasing global demand causing vaccine shortage, prompting the development of novel shingles vaccines.
View Article and Find Full Text PDFUrticarial Vasculitis Induced by Adalimumab Biosimilar in an Elderly Female With Hidradenitis Suppurativa: A Case Report.
Cureus
April 2024
General Practice, Ministry of Health, Qassim, SAU.
Article Synopsis
- Urticarial vasculitis (UV) is a rare type of inflammation in small blood vessels that can occur with anti-TNF-alpha medications, such as adalimumab biosimilars.
- A 72-year-old woman with multiple health issues developed severe angioedema and a widespread rash after starting treatment for hidradenitis suppurativa, leading to a diagnosis of drug-induced UV.
- Treatment successfully involved corticosteroids followed by doxycycline, emphasizing the need for dermatologists to recognize possible adverse effects of adalimumab biosimilars in patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!